Personalized dosimetry with intensification using90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis

Journal of Nuclear Medicine

Volumn 56, Issue 3, 2015, Pages 339-346

  Garin, Etienne ^a,b,c   Rolland, Yan ^a   Edeline, Julien ^a,b,c   Icard, Nicolas ^a   Lenoir, Laurence ^a,b,c   Laffont, Sophie ^a,c   Mesbah, Habiba ^a   Breton, Mathias ^a   Sulpice, Laurent ^c,d   Boudjema, Karim ^b,c,d   Rohou, Tanguy ^a   Raoul, Jean Luc ^e   Clement, Bruno ^c   Boucher, Eveline ^a,c  

^a CS 44229   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c INSERM   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e INSTITUT PAOLI CALMETTES   (France)

Author keywords

Hepatocellular carcinoma; MAA dosimetry; Personalization; Radioembolization

Indexed keywords

ALPHA FETOPROTEIN; MACROSALB TC 99M; MICROSPHERE Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; GLASS; MICROSPHERE; NICOTINAMIDE; SORAFENIB; YTTRIUM;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER PATIENT; CANCER RADIOTHERAPY; CHILD PUGH SCORE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DOSIMETRY; DRUG DISTRIBUTION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER SCINTISCANNING; LIVER TOXICITY; MALE; MEASUREMENT ACCURACY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RADIOEMBOLIZATION; RETROSPECTIVE STUDY; SELECTIVE INTERNAL RADIATION THERAPY; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; EUROPE; KAPLAN MEIER METHOD; LABORATORY DIAGNOSIS; LIVER; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PORTAL VEIN; PROCEDURES; RADIOMETRY; SCINTISCANNING; THROMBOSIS; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; EUROPE; FALSE POSITIVE REACTIONS; FEMALE; GLASS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PORTAL VEIN; RADIOMETRY; RETROSPECTIVE STUDIES; THROMBOSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84928106773     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.145177     Document Type: Article

References (24)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
2. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821-829.
3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
4. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med. 1994;35:1782-1787.
5. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.
6. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52:1741-1749.
7. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocarcinoma: a phase II study. Hepatology. 2013;57:1826-1837.
8. Sangro B, Carpanese L, Cianni R, et al.; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54:868-878.
9. Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. April 22, 2014 [Epub ahead of print].
10. 90Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55:168-197.
11. 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255-263.
12. 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057-1068.
13. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616-623.
14. Kokabi N, Galt JR, Xing M, et al. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. J Vasc Interv Radiol. 2014;25:277-287.
15. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009;49:1185-1193.
16. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79:163-171.
17. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60:192-201.
18. Memon K, Kulik L, Lewandowski RJ et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141:526-535.
19. 90yttrium microspheres. Dig Dis Sci. 2008;53:2556-2563.
20. Memon K, Kulik L, Lewandowski RJ, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58:73-80.
21. 90Y glass microspheres is linked to their transport in the arterial tree favoring a non-uniform trapping as observed in posttherapy PET imaging. J Nucl Med. 2014;55:135-140.
22. 90Y glass microspheres: long-term follow-up in a 134-patient cohort. Eur J Nucl Med Mol Imaging. 2014;41:486-493.
23. Lau WY, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82:401-407.
24. Kao YH, Tan EH, Ng CE, et al. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med. 2011;25:455-461.